Fränzel J.B. van Duijnhoven
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (22)
Supplementary Figure S5 shows the age-stratified calibration on 5- and 10-year absolute risks based on the PRS-enhanced model stratified by deciles of predicted risk in GERA European ancestry participants.
Year:
2025
Supplementary Figure S4 shows the family-history-stratified calibration on 5- and 10-year absolute risks based on the PRS-enhanced model stratified by deciles of predicted risk in GERA European ancestry participants.
Year:
2025
Background: Currently known associations between common genetic variants and colorectal cancer explain less than half of its heritability of 25%. As alcohol consumption has a J-shape association with colorectal cancer risk, nondrinking and heavy drinking are both risk factors for colorectal cancer. Methods: Individual-level data was pooled from the Colon Cancer Family Registry, Colorectal Transdisciplinary Study, and Genetics and Epidemiology of Colorectal Cancer Consortium to compare nondrinkers (≤1 g/day) and heavy drinkers (>28 g/day) with light-to-moderate drinkers (1–28 g/day) in GxE analyses. To improve power, we implemented joint 2df and 3df tests and a novel two-step method that modifies the weighted hypothesis testing framework. We prioritized putative causal variants by predicting allelic effects using support vector machine models. Results: For nondrinking as compared with light-to-moderate drinking, the hybrid two-step approach identified 13 significant SNPs with pairwise r 2 > 0.9 in the 10q24.2/ COX15 region. When stratified by alcohol intake, the A allele of lead SNP rs2300985 has a dose–response increase in risk of colorectal cancer as compared with the G allele in light-to-moderate drinkers [OR for GA genotype = 1.11; 95% confidence interval (CI), 1.06–1.17; OR for AA genotype = 1.22; 95% CI, 1.14–1.31], but not in nondrinkers or heavy drinkers. Among the correlated candidate SNPs in the 10q24.2/ COX15 region, rs1318920 was predicted to disrupt an HNF4 transcription factor binding motif. Conclusions: Our study suggests that the association with colorectal cancer in 10q24.2/ COX15 observed in genome-wide association study is strongest in nondrinkers. We also identified rs1318920 as the putative causal regulatory variant for the region. Impact: The study identifies multifaceted evidence of a possible functional effect for rs1318920.
Year:
2025
Background: Tobacco smoking is an established risk factor for colorectal cancer. However, genetically defined population subgroups may have increased susceptibility to smoking-related effects on colorectal cancer. Methods: A genome-wide interaction scan was performed including 33,756 colorectal cancer cases and 44,346 controls from three genetic consortia. Results: Evidence of an interaction was observed between smoking status (ever vs. never smokers) and a locus on 3p12.1 (rs9880919, P = 4.58 × 10 −8 ), with higher associated risk in subjects carrying the GG genotype [OR, 1.25; 95% confidence interval (CI), 1.20–1.30] compared with the other genotypes (OR P = 1.72 × 10 −8 ) and 8q24.23 (rs7005722, P = 2.88 × 10 −8 ). Subjects carrying the rs4151657 TT genotype showed higher risk (OR, 1.12; 95% CI, 1.09–1.16) compared with the other genotypes (OR CADM2 (3p12.1) and ATF6B (6p21.33). Conclusions: Our study identified novel genetic loci that may modulate the risk for colorectal cancer of smoking status and intensity, linked to tumor suppression and immune response. Impact: These findings can guide potential prevention treatments.
Year:
2025
Supplementary Figure S2 shows the sex-stratified calibration on 5- and 10-year absolute risks based on the PRS-enhanced model stratified by deciles of predicted risk in GERA European ancestry participants.
Year:
2025
Background: Polygenic risk scores (PRS) which summarize individuals’ genetic risk profile may enhance targeted colorectal cancer screening. A critical step towards clinical implementation is rigorous external validations in large community-based cohorts. This study externally validated a PRS-enhanced colorectal cancer risk model comprising 140 known colorectal cancer loci to provide a comprehensive assessment on prediction performance. Methods: The model was developed using 20,338 individuals and externally validated in a community-based cohort ( n = 85,221). We validated predicted 5-year absolute colorectal cancer risk, including calibration using expected-to-observed case ratios (E/O) and calibration plots, and discriminatory accuracy using time-dependent AUC. The PRS-related improvement in AUC, sensitivity and specificity were assessed in individuals of age 45 to 74 years (screening-eligible age group) and 40 to 49 years with no endoscopy history (younger-age group). Results: In European-ancestral individuals, the predicted 5-year risk calibrated well [E/O = 1.01; 95% confidence interval (CI), 0.91–1.13] and had high discriminatory accuracy (AUC = 0.73; 95% CI, 0.71–0.76). Adding the PRS to a model with age, sex, family and endoscopy history improved the 5-year AUC by 0.06 ( P P = 0.05) in the screening-eligible age and younger-age groups, respectively. Using a risk-threshold of 5-year SEER colorectal cancer incidence rate at age 50 years, adding the PRS had a similar sensitivity but improved the specificity by 11% ( P P = 0.04) with similar specificity. Conclusions: The proposed PRS-enhanced model provides a well-calibrated 5-year colorectal cancer risk prediction and improves discriminatory accuracy in the external cohort. Impact: The proposed model has potential utility in risk-stratified colorectal cancer prevention.
Year:
2025
Supplementary Figure S3 shows the endoscopy-history-stratified calibration on 5- and 10-year absolute risks based on the PRS-enhanced model stratified by deciles of predicted risk in GERA European ancestry participants.
Year:
2025
Background: Fatigue is often reported by colorectal cancer survivors and largely impacts their quality of life. Inflammation has been linked to fatigue mainly in patients with breast cancer. Therefore, we investigated how inflammation is longitudinally associated with fatigue in colorectal cancer survivors, up to 2 years posttreatment. Methods: A total of 257 patients from the ongoing Energy for life after ColoRectal cancer cohort study were included in the analysis. Plasma levels of IL6, IL8, IL10, TNFα, high-sensitivity C-reactive protein (hsCRP), and fatigue were measured at 6 weeks, 6, 12, and 24 months posttreatment. Fatigue was measured through the validated Checklist Individual Strength (CIS; total, 20–140), consisting of four subscales – subjective fatigue (8– 56 ), motivation ( 4–28 ), physical activity ( 3–21 ), and concentration ( 5–35 ), and the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 fatigue subscale (0–100). Linear mixed-models were used to assess the confounder-adjusted longitudinal associations between inflammatory markers and overall fatigue along with the subscales. Results: Mean levels of CIS fatigue decreased from 62.9 at 6 weeks to 53.0 at 24 months. In general, levels of inflammatory markers also decreased over time. No statistically significant longitudinal associations were found between IL6, IL8, IL10, TNFα, and fatigue. Higher levels of hsCRP were associated with more CIS fatigue (β per SD 3.21, 95% confidence interval (CI), 1.42–5.01) and EORTC fatigue (β 2.41, 95% CI, 0.72–4.10). Conclusions: Increased levels of hsCRP are longitudinally associated with more posttreatment fatigue in colorectal cancer survivors. Impact: These findings suggest that low-grade inflammation may play a role in fatigue reported by colorectal cancer survivors up to 2 years posttreatment.
Year:
2025
Supplementary methods show the details of study population, risk model development, calculation of the polygenic risk score, statistical analysis and funding of individual studies in GECCO and CORECT.
Year:
2025
Background Liver fat accumulation has been associated with impaired colorectal cancer prognosis. Associations may differ for colon and rectal cancer due to different disease mechanisms and dissemination patterns. Here, we investigated associations between liver fat and cancer recurrence, recurrence-free survival (RFS), and overall survival (OS) among 1596 individuals with stage I-III colon or rectal cancer. Methods Within a prospective cohort study, we used data from adults recently diagnosed with colon (n = 1080) or rectal (n = 516) cancer. Liver fat was evaluated using routine contrast-enhanced computed tomography (CT)-scans taken at diagnosis. Cox proportional hazards regression analyses adjusted for clinical and lifestyle-related variables were used to obtain hazard ratios (HRs) and 95% confidence intervals (95% CIs). Results During a median follow-up of 6.4 and 8.8 years, 247 (15%) recurrences (12% for colon and 22% for rectal cancer) and 418 (26%) deaths (25% for colon and 29% for rectal cancer) occurred, respectively. More liver fat was associated with an increased recurrence risk (HRT3vsT1 = 1.60, 95% CI = 1.02 to 2.50), worse RFS (HRT3vsT1 = 1.45, 95% CI = 1.05 to 2.00), and OS (HRT3vsT1 = 1.67, 95% CI = 1.20 to 2.33) among individuals with colon cancer. Liver fat was not associated with recurrence (HRT3vsT1 = 0.70, 95% CI = 0.42 to 1.18), RFS (HRT3vsT1 = 0.87, 95% CI = 0.59 to 1.30), or OS (HRT3vsT1 = 1.15, 95% CI = 0.74 to 1.80) among individuals with rectal cancer. Conclusion More liver fat was associated with poor clinical outcomes in patients with stage I-III colon cancer. Further studies are needed to confirm these findings and explore mechanistic routes linking liver fat to colon cancer prognosis.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (74)
Li Hsu
Fred Hutchinson Cancer Research Center
Polly Newcomb
University of Washington
Marc Gunter
International Agency for Research on Cancer
Tabitha Harrison
Fred Hutchinson Cancer Research Center
Konstantinos K. Tsilidis
-
Johannes H W de Wilt
Radboud University Medical Center
Martijn Bours
Associate Professor
University of Maastricht
Victor Moreno
Professor
University of Barcelona
Marina Evangelou
Senior Lecturer in Statistics
Imperial College London
Stephanie Breukink
Maastricht University Medical Centre
Susanna Larsson
Professor at Karolinska Institutet
Karolinska Institutet
Juan Pablo Lewinger
Associate Professor
University of Southern California
John Baron
Professor
University of North Carolina
David Drew
Assistant Professor of Medicine
Massachusetts General Hospital
Bernardus Jacobus Maria Witteman
professor
Wageningen University & Research
Eline H. van Roekel
University of Maastricht
Ulrike Peters
Fred Hutchinson Cancer Research Center
Jihyoun Jeon
University of Michigan
Matthew Devall
Assistant Professor
University of Virginia
Sophia Harlid
Umea University
Eric Kawaguchi
Assistant Professor
University of Southern California
Evertine Wesselink
Wageningen University & Research
Julie R Palmer
Boston University School of Medicine
Johanna Marianna Geleijnse
Wageningen University & Research
Elizabeth Platz
Professor
Johns Hopkins University
Renate Winkels
Wageningen University & Research
Yingye Zheng
Fred Hutchinson Cancer Research Center
Mariana C. Stern
Professor
University of Southern California
Gerard Bryan Gonzales
Associate Professor
Ghent University
Matty Weijenberg
Professor of Molecular Epidemiology of Cancer
University of Maastricht
Tim Bishop
University of Leeds
Elizabeth Hauser
Duke University
Richard Hayes
Professor of Population Health and Environmental Medicine
NYU School of Medicine
Mingyang Song
Associate Professor
Harvard University
Stéphane Bézieau
Université de Nantes
Virginia Díez-Obrero
Vrije Universiteit Amsterdam
Hongmei Nan
Professor
University of Indianapolis
Emmanouil Bouras
Research associate
Imperial College London
Alicja Wolk
Professor of Nutritional Epidemiology
Karolinska Institutet
Anna H. Wu
Professor
University of Southern California
Robert C. Grant
University Health Network
John Potter
Professor
University of Washington
Bethany Van Guelpen
Umea University
Li Li
University of Virginia
Iris Lansdorp-Vogelaar
Associate Professor
Erasmus University Medical Center
Dieuwertje Kok
Wageningen University & Research
Andrea Burnett-Hartman
Epidemiologist Program Director
Fred Hutchinson Cancer Research Center
Andrea Gsur
Medical University of Vienna
Loic Le Marchand
Professor
University of Hawaii
Edward A. Ruiz-Narváez
Associate Professor
University of Michigan School of Public Health
Elom K Aglago
Imperial College London
David Conti
Professor
Colorado School of Public Health
W. James Gauderman
professor
University of Southern California
Vicente Martín-Sánchez
JEFE DE GRUPO
Universidad de León
Paul Pharoah
Professor of Cancer Epidemiology
Cedars-Sinai Medical Center
Graham Casey
University of Virginia
Catherine Tangen
Fred Hutchinson Cancer Research Center
Satu Männistö
Finnish Institute for Health and Welfare
Kala Visvanathan
Professor
Johns Hopkins University
Jessica Petrick
Boston University
Daniel D. Buchanan
Senior Research Fellow
University of Melbourne
Michelle Cotterchio
Professor (status only)
University of Toronto
Annika Lindblom
Karolinska Institutet
Stephen Gruber
Professor
City Of Hope National Medical Center
Jochen Hampe
Scientific Speaker
Technische Universität Dresden
Anshul Kundaje
Associate Professor
Stanford University
Mark Jenkins
University of Melbourne
Peter T. Campbell
Professor
Albert Einstein College of Medicine
Graham Giles
Head of Research
-
Michael Hoffmeister
Professor of Epidemiology, Group leader, Deputy divison head
German Cancer Research Center (DKFZ)
Volker Arndt
Group leader
Deutsches Krebsforschungszentrum
Elizabeth Barry
Associate Professor
Dartmouth College Geisel School of Medicine
Pavel Vodička
senior researcher
Charles University
Jennifer Ose
Professorin (W2)
Hochschule Hannover
Make your next move.
Prepare your application
Review drafts before you send them.